Assetmark Inc. Has $3.74 Million Position in Zoetis Inc. (NYSE:ZTS)

Assetmark Inc. reduced its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 80.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,943 shares of the company’s stock after selling 97,360 shares during the period. Assetmark Inc.’s holdings in Zoetis were worth $3,738,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Darwin Wealth Management LLC acquired a new stake in shares of Zoetis in the 3rd quarter valued at about $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis in the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis in the 3rd quarter valued at about $33,000. Dunhill Financial LLC grew its stake in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares during the period. Finally, Atlantic Edge Private Wealth Management LLC grew its stake in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Zoetis stock opened at $170.34 on Friday. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33. The company’s 50 day moving average price is $166.72 and its two-hundred day moving average price is $176.78. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The stock has a market cap of $76.28 billion, a P/E ratio of 31.14, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. On average, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Analyst Upgrades and Downgrades

ZTS has been the subject of several research reports. Leerink Partners initiated coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Barclays lifted their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Friday. Finally, Piper Sandler lifted their price target on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis currently has an average rating of “Buy” and a consensus price target of $215.90.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.